Stanley Laman Group, Ltd. Exelixis, Inc. Transaction History

Stanley Laman Group, Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 19, 2023	BUY	$14.96 - $17.39 $213,823 - $248,555	14,293 New	14,293 $0
Q4 2019 Feb 04, 2020	SELL	$15.15 - $18.89 $195,525 - $243,794	-12,906 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$17.68 - $22.65 $10,961 - $14,043	620 Added 5.05%	12,906 $228,000
Q2 2019 Aug 01, 2019	BUY	$18.93 - $24.75 $232,573 - $304,078	12,286 New	12,286 $263,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stanley Laman Group, Ltd. with notifications on news.